Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06822829

Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting As Indolent Lymphoma

Status
Recruiting
Phase
Study type
Observational
Enrollment
50 (estimated)
Sponsor
Azienda USL Reggio Emilia - IRCCS · Other Government
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Most relapses of diffuse large B-cell lymphoma (DLBCL) occur as high-grade lymphoma within the first two years after diagnosis. Relapses as indolent lymphoma are rare events, and the true incidence of this phenomenon is unknown, since literature data are scarce/ and usually restricted to case reports. Analogously, reported treatment strategies are rather heterogeneous, since no standard of care is established and advanced age together with previous anthracycline exposure may narrow the therapeutic choice. The goal of this observational study is to assess epidemiological, clinical characteristics and survival of diffuse large b-cell lymphoma (DLBCL) relapsing as indolent lymphoma. More precisely, the study aims at identifying diagnostic and imaging features associated with relapse as indolent lymphoma and at evaluating disease response to selected therapies.

Conditions

Timeline

Start date
2024-08-19
Primary completion
2026-08-01
Completion
2026-08-01
First posted
2025-02-12
Last updated
2025-02-12

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT06822829. Inclusion in this directory is not an endorsement.